Skip to main content
. 2015 Apr 27;5(1):e1025194. doi: 10.1080/2162402X.2015.1025194

Figure 5.

Figure 5.

(A) Treatment schedule of mice used in in vivo experiments (B) Engraftment of Vγ9Vδ2+ γδT cells in NSG mice bearing TC71 Ewing's sarcoma (representative of six mice sampled) or Kelly neuroblastoma (representative of eight mice sampled) xenografts. Samples taken after culling, following three serial intravenous injections of 1 × 106 γδT cells. (C) Fold change in tumor size of TC71 xenografts in NSG mice receiving Vγ9Vδ2 + zoledronate, Vγ9Vδ2 + zoledronate + ch14.18/CHO or zoledronate + ch14.18/CHO (D) – fold change in tumor size of Kelly xenografts in NSG mice receiving Vγ9Vδ2 + zoledronate, Vγ9Vδ2 + zoledronate + ch14.18/CHO or zoledronate + ch14.18/CHO.